Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imatinib with intensive versus reduced chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia
MOH_2019-06-04_006048Phase 3Not yet recruiting
- Sponsor
- דר' שרה אליצור
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by דר' שרה אליצור. Primary endpoints: Disease-free survival and Treatment-related toxicity. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2019-06-04_006048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-04_006048.